StreetAlpha.app
Home › Stocks › CHRS

Coherus Oncology, Inc. (CHRS)

$0.49
▼ −3.38%
LAST CLOSE · NOV 17

Coherus Oncology develops and sells LOQTORZI, a cancer medicine, and is developing two other cancer treatment candidates in clinical studies. It last closed at $0.49 on Nov 17, down 3.38% on the day. The average 12-month price target from 2 analysts is $7.50 (+1434.4% from the last close), with a high of $8.00 and a low of $7.00.

AI Auto Pilots
Is CHRS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$53.6M
+44.4% vs a year ago
Net income
−$135.9M
−187.7% vs a year ago
EPS (diluted)
−$1.00
−175.2% vs a year ago
Gross margin
69.8%
$37.4M gross profit
Valuation
Market cap
$75.5M
154.5M shares
P/E
–
No P/E while losing money
Price to sales
1.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$53.5M
At Sep 30
Shareholder equity
$25.2M
Shares outstanding
154.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $326.6M$326.6MFY2021FY2022: $211.0M$211.0MFY2022FY2023: $257.2M$257.2MFY2023FY2024: $26.4M$26.4MFY2024FY2025: $42.2M$42.2MFY2025

From CHRS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated CHRS in the past 90 days, not enough for a consensus
Average 12-month target
$7.50
▲ 1434.4% upside

Based on 2 analysts who set a price target on CHRS in the past 90 days. The average target is $7.50, with a high of $8.00 and a low of $7.00, compared with the last close of $0.49.

Low $7.00Avg $7.50High $8.00
Blue marker: last close $0.49
Highest target$8.00
Average target$7.50
Lowest target$7.00
Latest rating changes
GuggenheimTarget lowered
Nov 10Buy$10 → $8
HC Wainwright & Co.Assumed coverage
Oct 29Buy$7
GuggenheimMaintained
Aug 7Buy$10
GuggenheimInitiated
May 11Buy$12
DateFirmActionRatingPrice target
Nov 10GuggenheimTarget loweredBuy$10 → $8
Oct 29HC Wainwright & Co.Assumed coverageBuy$7
Aug 7GuggenheimMaintainedBuy$10
May 11GuggenheimInitiatedBuy$12
Loading…

Technical Analysis

CHRS · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 64% below its 20 day and 109% below its 50 day average. It is 197% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot at $0.47, and the nearest resistance the Pivot R1 at $0.51.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.7%/day
Key levels
$2.6252 week high+434.7%
$1.45200 day average+195.9%
$1.21100 day average+146.9%
$1.09Swing high (Oct 15)+122.4%
$1.0250 day average+108.2%
$0.8020 day average+63.3%
$0.51Pivot R1+4.1%
$0.49Last close
$0.47Pivot−4.1%
$0.45Pivot S1−8.2%
$0.4352 week low−12.2%
Indicators
RSI (14)27.12Oversold below 30Oversold
MACD-0.15Below its signal lineBearish
Stochastic4.8Near the bottom of its rangeOversold
ADX (14)33.6Trending down
Williams %R-92.5Oversold below −80, overbought above −20Oversold
CCI (20)-135.7Oversold below −100, overbought above 100Oversold
Rate of change−39.3%Change over 10 sessionsBearish
ATR (14)$0.09Typical daily range, 17.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CHRS

What happened before

See how CHRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CHRS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CHRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CHRS in the last 90 days.

Loading…

See today’s whale options flow across the market →

CHRS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼56 buying vs 74 selling
  • ▼Held by funds -2.6 pts
  • ▼Funds holding -12
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding135147−8.2%
In funds' top 10110.0%
Held by funds42.9%45.5%−2.6 pts
New / increased18 / 3810 / 62−22.2%
Reduced / sold out45 / 2939 / 20+25.4%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CHRS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CHRS is in one of them and how their past CHRS trades turned out.

CHRS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CHRS in an article yet. Here's the latest on the wider market.

About Coherus Oncology

Coherus Oncology is a cancer drug company based in Redwood City, California. Its main product is LOQTORZI, an antibody medicine that blocks the PD-1 pathway. It is approved in the United States for nasopharyngeal carcinoma, a cancer of the upper throat, and the company sells it for treating cancer patients. The company is also developing two other cancer treatment candidates in clinical studies, aimed at cancers such as liver, head and neck, and colorectal cancer.

Headquarters
Redwood City, CA
Founded
2010